Intensity Therapeutics, Inc. (INTS) has shared an announcement.
Intensity Therapeutics, Inc. has expanded its Board of Directors by appointing Thomas I. H. Dubin, bringing the total number of directors to five. Dubin joins as an independent director and will also serve on the Audit Committee, helping the company to meet Nasdaq’s audit committee requirements after a recent non-compliance issue. His addition is not based on any pre-existing agreements, and he will receive standard compensation along with stock options.
For an in-depth examination of INTS stock, go to TipRanks’ Stock Analysis page.
